{
    "root": "23d1a15a-1ba9-46a2-9851-25a00475c0a3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Paliperidone",
    "value": "20250508",
    "ingredients": [
        {
            "name": "PALIPERIDONE",
            "code": "838F01T721",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_82978"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "ETHYLCELLULOSE, UNSPECIFIED",
            "code": "7Z8S9VYZ4B"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_168426"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16134"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "indications": {
        "text": "paliperidone atypical antipsychotic agent indicated treatment schizophrenia ( 1.1 ) \u2022 adults : efficacy established three 6-week trials one maintenance trial . ( 14.1 ) \u2022 adolescents ( ages 12 17 ) : efficacy established one 6-week trial . ( 14.1 ) treatment schizoaffective disorder monotherapy adjunct mood stabilizers and/or antidepressants . ( 1.2 ) \u2022 efficacy established two 6-week trials adult patients . ( 14.2 )",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "schizoaffective disorder (DOID:5418)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5418"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "initial dose recommended dose maximum dose schizophrenia - adults ( 2.1 ) 6 mg/day 3 12 mg/day 12 mg/day schizophrenia-adolescents ( 2.1 ) weight < 51kg 3 mg/day 3 6 mg/day 6 mg/day weight \u2265 51kg 3 mg/day 3 12 mg/day 12 mg/day schizoaffective disorder - adults ( 2.2 ) 6 mg/day 3 12 mg/day 12 mg/day \u2022 tablet swallowed whole chewed , divided , crushed . ( 2.3 )",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "schizoaffective disorder (DOID:5418)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5418"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "paliperidone extended-release tablets available following strengths packages . 3 mg tablets white off-white , circular , biconvex , beveled edged , film-coated tablets imprinted \u201c 765 \u201d black ink one side plain side . cartons 100 extended-release tablets ( 10 extended-release tablets blister pack x 10 ) , ndc 0904-6935-61 6 mg tablets yellow , circular , biconvex , beveled edged , film-coated tablets imprinted \u201c 766 \u201d black ink one side plain side . cartons 100 extended-release tablets ( 10 extended-release tablets blister pack x 10 ) , ndc 0904-6936-61 9 mg tablets pink , circular , biconvex , beveled edged , film-coated tablets imprinted \u201c 767 \u201d black ink one side plain side . cartons 100 extended-release tablets ( 10 extended-release tablets blister pack x 10 ) , ndc 0904-6937-61 storage handling store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . protect moisture.keep reach children .",
    "adverseReactions": "paliperidone contraindicated patients known hypersensitivity either paliperidone risperidone , excipients paliperidone extended-release tablet formulation . hypersensitivity , including anaphylactic angioedema , reported patients treated risperidone patients treated paliperidone . paliperidone metabolite risperidone .",
    "indications_original": "Paliperidone is an atypical antipsychotic agent indicated for Treatment of schizophrenia ( 1.1 ) \u2022 Adults: Efficacy was established in three 6-week trials and one maintenance trial. ( 14.1 ) \u2022 Adolescents (ages 12 to 17): Efficacy was established in one 6-week trial. ( 14.1 ) Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. ( 1.2 ) \u2022 Efficacy was established in two 6-week trials in adult patients. ( 14.2 )",
    "contraindications_original": "Initial Dose Recommended Dose Maximum Dose Schizophrenia - adults ( 2.1 ) 6 mg/day 3\u00a0 to\u00a0 12 mg/day 12 mg/day Schizophrenia-adolescents ( 2.1 ) Weight < 51kg 3 mg/day 3\u00a0 to\u00a0 6 mg/day 6 mg/day Weight \u2265 51kg 3 mg/day 3\u00a0 to\u00a0 12 mg/day 12 mg/day Schizoaffective disorder - adults ( 2.2 ) 6 mg/day 3\u00a0 to\u00a0 12 mg/day 12 mg/day \u2022 Tablet should be swallowed whole and should not be chewed, divided, or crushed. ( 2.3 )",
    "warningsAndPrecautions_original": "Paliperidone extended-release tablets are available in the following strengths and packages.\n                     3 mg tablets are white to off-white, circular, biconvex, beveled edged, film-coated tablets imprinted with \u201c765\u201d in black ink on one side and plain on the other side.\n                     Cartons of 100 extended-release tablets (10 extended-release tablets each blister pack x 10), NDC 0904-6935-61\u00a0\n                     6 mg tablets are yellow, circular, biconvex, beveled edged, film-coated tablets imprinted with \u201c766\u201d in black ink on one side and plain on the other side.\n                     Cartons of 100 extended-release tablets (10 extended-release tablets each blister pack x 10), NDC 0904-6936-61\n                     9 mg tablets are pink, circular, biconvex, beveled edged, film-coated tablets imprinted with \u201c767\u201d in black ink on one side and plain on the other side.\n                     Cartons of 100 extended-release tablets (10 extended-release tablets each blister pack x 10), NDC 0904-6937-61\n                     \n                     \n                     Storage and Handling\n                     Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted between 15\u00b0 and 30\u00b0C (59\u00b0 and 86\u00b0F) [see USP Controlled Room Temperature]. Protect from moisture.Keep out of reach of children.",
    "adverseReactions_original": "Paliperidone is contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone extended-release tablet formulation. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. Paliperidone is a metabolite of risperidone.",
    "drug": [
        {
            "name": "Paliperidone",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_82978"
        }
    ]
}